{"filing":{"accession_number":"0001193125-26-269635","cik":"0001672619","ticker":"ELVN","company_name":"Enliven Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"d152122d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526269635/d152122d8k.htm"},"events":[{"id":10330,"run_id":9060,"accession_number":"0001193125-26-269635","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.93,"summary":"Enliven Therapeutics entered into an underwriting agreement on June 11, 2026 for a registered public offering of 8,933,334 shares of common stock at $37.50 per share, plus 1,733,333 pre-funded warrants, with expected net proceeds of approximately $376 million (or $432.4 million if the underwriter option is exercised in full). The offering will dilute existing shareholders and materially affect the company's capital structure and ownership percentages.","company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6619,"accession_number":"0001193125-26-269635","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Enliven Therapeutics entered into an underwriting agreement on June 11, 2026 for a public offering of 8,933,334 shares of common stock at $37.50 per share, plus 1,733,333 pre-funded warrants, with expected net proceeds of approximately $376 million (or $432.4 million if the underwriter option is exercised in full). This is a registered public offering of equity securities that will dilute existing shareholders and materially affect the company's capital structure and ownership percentages.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:03:25.608812+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6620,"accession_number":"0001193125-26-269635","item_number":"7.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses pricing of an \"Offering\" announced via press release on June 11, 2026, with forward-looking statements referencing \"expected net proceeds from the Offering\" and \"expected closing date of the Offering.\" While the specific terms are not detailed in this Item 7.01 excerpt, the language and structure indicate a securities offering (likely equity or convertible debt) that would be dilutive to existing shareholders. This is a material event affecting capitalization and investor interests.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:03:25.608812+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6619,"accession_number":"0001193125-26-269635","item_number":"1.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Enliven Therapeutics entered into an underwriting agreement on June 11, 2026 for a public offering of 8,933,334 shares of common stock at $37.50 per share, plus 1,733,333 pre-funded warrants, with expected net proceeds of approximately $376 million (or $432.4 million if the underwriter option is exercised in full). This is a registered public offering of equity securities that will dilute existing shareholders and materially affect the company's capital structure and ownership percentages.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:03:25.608812+00:00","company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","filing_date":"2026-06-12"},{"id":6620,"accession_number":"0001193125-26-269635","item_number":"7.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses pricing of an \"Offering\" announced via press release on June 11, 2026, with forward-looking statements referencing \"expected net proceeds from the Offering\" and \"expected closing date of the Offering.\" While the specific terms are not detailed in this Item 7.01 excerpt, the language and structure indicate a securities offering (likely equity or convertible debt) that would be dilutive to existing shareholders. This is a material event affecting capitalization and investor interests.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:03:25.608812+00:00","company_name":"Enliven Therapeutics, Inc.","ticker":"ELVN","filing_date":"2026-06-12"}]}